Use of the comet assay for assessment of drug resistance and its modulation in vivo
1998

Using the Comet Assay to Study Drug Resistance in Cancer

publication Evidence: moderate

Author Information

Author(s): P Huang, PL Olive, RE Durand

Primary Institution: BC Cancer Research Centre

Hypothesis

The comet assay can identify and monitor tumor cell responsiveness to anti-cancer agents in vivo.

Conclusion

The comet assay effectively predicts tumor resistance to etoposide and the efficacy of multidrug resistance reversing agents.

Supporting Evidence

  • The comet assay can provide an index of sensitivity to etoposide.
  • Modulators like verapamil and dipyridamole increased the effectiveness of etoposide.
  • The assay can detect small populations of resistant cells.
  • The comet assay is applicable to various chemotherapy agents.

Takeaway

Scientists used a special test called the comet assay to see how well cancer cells respond to a drug. They found it helps understand which tumors are resistant to treatment.

Methodology

The study involved using the comet assay to measure DNA damage in various tumor cell lines treated with etoposide, both in vitro and in vivo.

Limitations

The comet assay can only assess drugs that cause measurable DNA damage and can only be performed on accessible tumors.

Participant Demographics

The study included rodent and human tumor cell lines, specifically Chinese hamster V79 fibroblasts, WiDr colon adenocarcinoma, and U87 glioblastoma.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication